---
title: "在媒体报道强生公司正在洽谈收购 Protagonist Therapeutics 后，该公司股价飙升"
description: "Protagonist Therapeutics 的股价上涨 28.3%，达到历史最高点 86 美元。《华尔街日报》报道称，强生公司正在与 PTGX 进行收购谈判，消息来源为知情人士。交易并未得到保证，具体讨论的细节尚未得知。根据 LSEG 数据，PTGX 截至上一个交易日的市值为 41.7 亿美元。截至上一个交易日，该股今年以来上涨 71.4%"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260666215.md"
published_at: "2025-10-10T15:38:23.000Z"
---

# 在媒体报道强生公司正在洽谈收购 Protagonist Therapeutics 后，该公司股价飙升

> Protagonist Therapeutics 的股价上涨 28.3%，达到历史最高点 86 美元。《华尔街日报》报道称，强生公司正在与 PTGX 进行收购谈判，消息来源为知情人士。交易并未得到保证，具体讨论的细节尚未得知。根据 LSEG 数据，PTGX 截至上一个交易日的市值为 41.7 亿美元。截至上一个交易日，该股今年以来上涨 71.4%

Protagonist Therapeutics (PTGX.O) 的股价上涨 28.3%，创下 86 美元的历史新高

《华尔街日报》报道，强生公司 (JNJ.N) 正在讨论收购 PTGX，消息来源为知情人士

交易并不保证，具体讨论的细节尚未得知 - WSJ

截至上一个交易日，PTGX 的市值为 41.7 亿美元 - LSEG 数据

截至上一个交易日，股票年初至今上涨 71.4%

### Related Stocks

- [PTGX.US - Protagonist治疗](https://longbridge.com/zh-CN/quote/PTGX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Protagonist Therapeutics (PTGX) to Release Earnings on Friday | Protagonist Therapeutics (NASDAQ:PTGX) is set to release its Q4 2025 earnings on February 20, with analysts expecting a  | [Link](https://longbridge.com/zh-CN/news/275855554.md) |
| Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Shareholder Returns | Protagonist Therapeutics (PTGX) is under investor scrutiny following its recent trading activity, closing at $81.93. Des | [Link](https://longbridge.com/zh-CN/news/275847121.md) |
| Johnson & Johnson EVP Vanessa Broadhurst Disposes of Common Shares | Vanessa Broadhurst, EVP of Global Corp Affairs at Johnson & Johnson, has disposed of common shares in the company. The f | [Link](https://longbridge.com/zh-CN/news/276293532.md) |
| 5,056 Shares in Johnson & Johnson $JNJ Acquired by Uniting Wealth Partners LLC | Uniting Wealth Partners LLC acquired 5,056 shares of Johnson & Johnson (NYSE: JNJ) in Q3, valued at approximately $938,0 | [Link](https://longbridge.com/zh-CN/news/276006840.md) |
| Key facts: J&J liable for cancer in talc case; $30M lawsuit filed against lenders | A Pennsylvania jury found Johnson & Johnson liable for cancer linked to its talc baby powder, awarding $250,000 to a pla | [Link](https://longbridge.com/zh-CN/news/275986663.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。